Traynor Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Traynor Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-13,404	Closed	-$537K	–	160
2016 Q4	$537K	Sell	13,404 -2,092	-14%	-$94.7K	0.36%	64
2016 Q3	$686K	Sell	15,496 -750	-5%	-$37.4K	0.48%	46
2016 Q2	$744K	Sell	16,246 -3,000	-16%	-$138K	0.58%	40
2016 Q1	$761K	Sell	19,246 -16,185	-46%	-$642K	0.61%	36
2015 Q4	$2M	Buy	35,431 +1,835	+5%	+$93.3K	1.44%	17
2015 Q3	$1.34M	Buy	33,596 +505	+2%	+$24.4K	1.15%	20
2015 Q2	$1.58M	Buy	33,091 +606	+2%	+$25.7K	1.32%	14
2015 Q1	$1.29M	Buy	32,485 +15,815	+95%	+$566K	1.24%	14
2014 Q4	$372K	Buy	+16,670	New	+$316K	0.43%	56

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Traynor Capital Management's NBIX Position: Q1 2017 in Review

Traynor Capital Management sold out of Neurocrine Biosciences (NBIX) in Q1 2017, closing a stake of 13,404 shares — an estimated $537K sold.

Traynor Capital Management first reported a position in NBIX in Q4 2014 and held it in 9 quarters. The position peaked at $2M in Q4 2015. 218 funds tracked by Wall St. Rank hold NBIX as of Q1 2017.

Traynor Capital Management reported no remaining Neurocrine Biosciences position as of Q1 2017 after selling out during the quarter.
Traynor Capital Management sold 13,404 Neurocrine Biosciences shares in Q1 2017, an estimated $537K.
Traynor Capital Management first reported a position in Neurocrine Biosciences in Q4 2014 and held it in 9 quarters.
Traynor Capital Management's Neurocrine Biosciences position peaked at $2M in Q4 2015.
218 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2017.

Based on Traynor Capital Management's 13F filing for Q1 2017, filed 11 May 2017.